Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CTSV | O60911 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063806 | 1.00 | MEN1 (0.57) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL29444157 | 1.00 | MEN1 (0.57) | MEN1KMT2AALDH1A1CTSVCTSL | |
| Nitric Acid SCHEMBL7007347 | 0.98 | MEN1 (0.56) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL1783172 | 0.93 | MEN1 (0.52) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL30820477 | 0.92 | CTSV (0.50) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL18660057 | 0.92 | CTSV (0.50) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL2089147 | 0.92 | MEN1 (0.54) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL874114 | 0.92 | MEN1 (0.54) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL29729282 | 0.92 | MEN1 (0.54) | MEN1KMT2AALDH1A1CTSVCTSL | |
| SCHEMBL31738326 | 0.91 | CTSV (0.58) | MEN1KMT2AALDH1A1CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026083-B | Heterocyclic inhibitors of tyrosine kinases | 德州大学系统董事会 | 2024-07-09 | — | — | CN | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| WO-2022170917-A1 | POLYCYCLIC PYRIMIDINE DERIVATIVE AS SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220162172-A1 | QUINAZOLINONE COMPOUNDS | CEREPEUT, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-3962908-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | Board of Regents, The University of Texas System (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114026083-A | Heterocyclic inhibitors of tyrosine kinases | 德州大学系统董事会 | 2022-02-08 | — | — | CN | disclosed |
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| WO-2006069740-A1 | 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060142570-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1674466-A1 | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | MEN1 403/4885KMT2A 834/4885ALDH1A1 4417/4885 |
| US-20060142570-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | MEN1 2616/4885KMT2A 3416/4885ALDH1A1 139/4885 |
| US-20220162172-A1 | QUINAZOLINONE COMPOUNDS | NDUFAB1, NDUFV1, NDUFV2 | MEN1 4562/4885KMT2A 4531/4885ALDH1A1 1693/4885 |
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | MEN1 2444/4885KMT2A 1200/4885ALDH1A1 2546/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | MEN1 3007/4885KMT2A 3313/4885ALDH1A1 3117/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | MEN1 403/4885KMT2A 834/4885ALDH1A1 4417/4885 |
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | ERBB2, ERBB3, EGFR | MEN1 4107/4885KMT2A 2294/4885ALDH1A1 2730/4885 |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | ERBB2, ERBB3, EGFR | MEN1 4107/4885KMT2A 2294/4885ALDH1A1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.